Cialis Reaches $1 Billion Global Sales Milestone
Lilly ICOS LLC (NYSE: LLY and Nasdaq: ICOS), marketer of Cialis, a PDE5 inhibitor indicated for the treatment of erectile dysfunction (ED), announced today that the drug has achieved $1 billion in global sales since launching in Europe a little more than two years ago.
In January 2005, tadalafil became the leading ED treatment in France, a lead it has held through May, based on the latest market share data. It is also performing very well in other countries, including the United Kingdom, Italy, Germany, United States, Canada, Australia, Mexico and Brazil.
“We are very pleased with the performance of Cialis and the steady development of the brand since its launch two years ago,” said Rich Pilnik, President of Lilly’s EMEA region. “Millions of men suffer from erectile dysfunction and the growth of the market demonstrates that patients are speaking to their healthcare providers about ED and seeking treatment options.”
Tadalafil was the second PDE5 inhibitor drug to become available in Europe. It is currently marketed in approximately 100 countries including the United States, Australia, Brazil, Mexico, Canada and across Europe and Asia.
“Passing the US$1 billion mark is an important milestone for Lilly ICOS and a great accomplishment for the Cialis team,” said Paul Clark, Chairman and Chief Executive Officer of ICOS Corporation. “Since 2003, men with erectile dysfunction have had a choice of oral treatments for their condition — a condition which may impact on relationships and daily life.” In a clinical trial conducted in 2005, 77 percent of men experienced improved erections after taking a 20 mg dose of Cialis.
About Erectile Dysfunction (ED)
ED is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. Erectile dysfunction affects an estimated 189 million men worldwide. Experts believe that 80 percent to 90 percent of ED cases are related to a physical or medical condition, such as diabetes, cardiovascular diseases, and prostate cancer treatment, while 10 percent to 20 percent are due to psychological causes. In many cases, however, both psychological and physical factors contribute to the condition.
SOURCE: Lilly-ICOS Press Release, July 21, 2005
[tags]Cialis, Lilly-ICOS, Eli Lilly, Cialis sales, erectile dysfunction, ED[/tags]
- Cialis Overtakes Viagra, Becomes #1 ED Pill in France
Lilly ICOS LLC reported today that Cialis®, the only erectile dysfunction treatment clinically proven to work up to 36 hours for most men, has surpassed Viagra® in France for the second consecutive month. - Sales of Cialis Up, But Real Test Is With Rival Viagra
The numbers that came out yesterday for Cialis — from Bothell-based Icos and its partner, Eli Lilly — showed that the so-called “weekend pill” generated $109 million in sales for the first nine months of the year, from 45 countries where it is approved. The companies expect U.S. approval for Cialis by year’s end. - Cialis Sales End 2004 #2 to Rival Viagra
Cialis ended the year with one weak quarter, but in the first full year of the global battle among erectile dysfunction drugs, it still finished where many expected — a popular but distant No. 2 to Viagra.
